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AbstrAct
Introduction With the rising prevalence of type 2 diabetes 
in Australia, screening and earlier diagnosis is needed to 
provide opportunities to intervene with evidence-based 
lifestyle and treatment options to reduce the individual, 
social and economic impact of the disease. The objectives 
of the Pharmacy Diabetes Screening Trial are to compare 
the clinical effectiveness and cost-effectiveness of three 
screening models for type 2 diabetes in a previously 
undiagnosed population.
Methods and analysis The Pharmacy Diabetes 
Screening Trial is a pragmatic cluster randomised 
controlled trial to be conducted in 363 community 
pharmacies across metropolitan, regional and remote 
areas of Australia, randomly allocated by geographical 
clusters to one of three groups, each with 121 
pharmacies and 10 304 screening participants. The three 
groups are: group A: risk assessment using a validated 
tool (AUSDRISK); group B: AUSDRISK assessment 
followed by point-of-care glycated haemoglobin testing; 
and group C: AUSDRISK assessment followed by point-of-
care blood glucose testing. The primary clinical outcome 
measure is the proportion of newly diagnosed cases of 
type 2 diabetes. Primary outcome comparisons will be 
conducted using the Cochran-Mantel-Haenszel test to 
account for clustering. The secondary clinical outcomes 
measures are the proportion of those who (1) are referred 
to the general practitioner (GP), (2) take up referral to 
the GP, (3) are diagnosed with pre-diabetes, that is, 
impaired glucose tolerance or impaired fasting glucose 
and (4) are newly diagnosed with either diabetes or pre-
diabetes. The economic outcome measure is the average 
cost (direct and indirect) per confirmed new case of 
diagnosed type 2 diabetes based on the incremental net 
trial-based costs of service delivery and the associated 
incremental longer term health benefits from a health 
funder perspective.
Ethics and dissemination The protocol has been 
approved by the Human Research Ethics Committees at 
University of Sydney and Deakin University. Results will be 
available on the Sixth Community Pharmacy Agreement 
website and will be published in peer reviewed journals.
trial registration number ACTRN12616001240437; Pre-
results.
bAckground
Type 2 diabetes mellitus (T2DM) is a chronic 
metabolic disorder characterised by the 
progressive failure of insulin secretion and/or 
increasing resistance of body tissues to insulin 
resulting in high blood glucose levels (hyper-
glycaemia).1 In Australia, the estimated prev-
alence of diagnosed T2DM increased from 
1.5% in 1989/1990 to 4.4% in 2014/2015.2 3 
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strengths and limitations of this study
 ► The study will include a nationally representative 
sample of both pharmacies and the population at 
risk of type 2 diabetes.
 ► The results will inform the potential real-world 
effectiveness of each intervention at a population 
level.
 ► Notwithstanding standardised approaches and 
clear documentation for data collection, some data 
obtained from pharmacists may be inaccurate or 
incomplete.
 ► Recruitment of screening participants by 
pharmacists may not achieve the expected uptake.
 ► Verification of whether there has been a diagnosis 
of type 2  diabetes  mellitus or pre-diabetes may 
be impossible for a small proportion of referred 
screening participants whose diabetes testing 
does not trigger National Diabetes Support Scheme 
registration and where follow-up with the patient, 
pathology lab and general  practitioner cannot be 
achieved or otherwise fails to confirm an outcome.
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Currently, there are approximately 1.2 million Australians 
with diagnosed T2DM and an estimated further 500 000 
with undiagnosed T2DM.4 5 In addition, almost one in 
six Australian adults (more than 2 million inintdividuals) 
over the age of 25 years is affected by pre-diabetes, that is, 
impaired glucose tolerance (IGT) or impaired fasting 
glucose (IFG), in which blood glucose levels are elevated 
but not high enough to be diagnosed with T2DM.6 Unde-
tected diabetes or pre-diabetes have implications for the 
health system and for individuals who are unaware of 
their condition and consequently do not have the oppor-
tunity to reduce their risk of developing chronic condi-
tions caused by uncontrolled hyperglycaemia, including 
macrovascular complications (eg, peripheral vascular 
disease, myocardial infarction, cardiovascular disease and 
stroke) and microvascular complications (eg, diabetic 
kidney disease, peripheral sensory neuropathy and 
diabetic retinopathy).6–10 There is often a latent period of 
many years with no symptoms before the disease is diag-
nosed, and comorbidities and complications may already 
have developed at diabetes diagnosis.11 12 
Studies have shown that the progression of diabetes 
and its complications can be reduced or delayed by life-
style changes and pharmacotherapy.13–15 These findings 
highlight the need for more effective screening of the 
general population to facilitate increased risk identifica-
tion and effective early management to reduce the risk of 
developing T2DM and its complications.
Many risk factors for T2DM are increasing in prev-
alence in line with increasing age and obesity. Since 
1994, the proportion of Australia’s population aged 
65 years and over increased from 11.8% to 14.7%.3 In 
2014–2015, 11.2 million (63.4%) of Australians over 
the age of 18 years were overweight or obese and this 
increased with geographic remoteness and lower socio-
economic status.3 Certain ethnicities have a higher 
prevalence of T2DM; Pacific Islander, southern Euro-
pean or Asian backgrounds are twice as likely, and 
Aboriginal and Torres Strait Islanders four times more 
likely, compared with other Australians, to have devel-
oped diabetes within 5 years based on self-report and 
measured data.16–18
The social, human and economic impact of T2DM in 
Australia has led to the development of the Australian 
National Diabetes Strategy.19 This strategy aims to coor-
dinate existing healthcare resources across all levels 
of government to reduce the impact of diabetes in the 
community. One such resource is community pharmacy. A 
recent review of pharmacy-based screening programmes 
reported that community pharmacies are feasible sites for 
screening and that a significant number of risk factors, 
such as high blood pressure, cholesterol and diabetes 
risk, were correctly identified in community pharma-
cies.20 There are more than 5000 community pharmacies 
in Australia with an extensive distribution throughout 
metropolitan, regional and remote areas.21 In addition, 
the overwhelming majority (94%) of Australians reported 
using a pharmacy in 2012,22 providing an opportunity 
to engage people along the health spectrum, including 
hard-to-reach populations who do not use other health 
services.
Australian pharmacies currently use a variety of means 
to test for diabetes and diabetes risk, including the use 
of AUSDRISK, a 10-item questionnaire that has been 
validated to predict risk of progression to T2DM over a 
5-year period in a diverse ethnic population. It includes 
questions based on age, sex, ethnicity, family history 
of diabetes, history of abnormal glucose metabolism, 
smoking status, current hypertensive treatment, phys-
ical activity, fruit and vegetable consumption and waist 
circumference to generate a risk score.
Other methods include random and fasting small capil-
lary blood glucose testing (scBGT) and, to a lesser extent, 
with point-of-care (POC) glycated haemoglobin (HbA1c) 
testing. The addition of a subsequent blood glucose test 
for those with AUSDRISK score ≥12 has been shown to be 
a more effective approach to screening, compared with 
using the AUSDRISK alone.23–26
Despite mounting evidence to support the feasibility 
and value of pharmacy as a component of population 
screening efforts, few studies, to date, have sought to 
determine the comparative effectiveness or cost-effec-
tiveness of different screening intervention options.23 24 
As such, the optimal approach to pharmacy screening 
remains uncertain. The Pharmacy Diabetes Screening 
Trial (PDST) aims to compare the diagnostic and 
economic outcomes for several evidence-based and prag-
matic models of diabetes screening in a community phar-
macy setting.
An expert panel consisting a range of stakeholders 
with expertise in diabetes, including representatives 
from The Boden Institute at University of Sydney; Austra-
lian Diabetes Society; Australian Diabetes Educators 
Association; Royal Australian College of General Practi-
tioners (RACGP); Pharmaceutical Society of Australia; 
Community Pharmacy; PDST Research team; Diabetes 
Australia; Department of Health; and Trials Advisory 
Group has been established to provide guidance on (1) 
the trial design; (2) communication strategies; and (3) 
how to support the engagement, recruitment and reten-
tion of participants (4) trial monitoring.
trial objectives
The objectives of the PDST are to compare the effective-
ness and cost-effectiveness of three different pharma-
cy-based screening models:
1. AUSDRISK alone (group A)
2. AUSDRISK followed by a POC test for HbA1c (group 
B)
3. AUSDRISK followed by a POC scBGT (group C).
Hypotheses
The primary null hypothesis is that there will be no 
differences between groups A and B or C in the propor-
tion of participants who are newly diagnosed with 
diabetes.
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Table 1 Statewide distribution of the pharmacies according 
to residential location
State or territory Metro Regional Remote Total
New South Wales 80 25 3 108
Victoria 59 25 2 86
Queensland 39 28 5 72
South Australia 14 9 7 30
Western Australia 22 6 6 34
Tasmania 0 11 3 14
Northern Territory 0 7 4 11
Australian Capital 
Territory
8 0 0 8
Australia total 222 111 30 363
Metro represents the Australian Bureau of Statistics (ABS) 
category: ‘Major Cities of Australia’. Regional represents the 
ABS categories: ‘Inner Regional Australia’ and ‘Outer Regional 
Australia’. Remote represents the ABS categories: ‘Remote 
Australia’ and ‘Very Remote Australia’. Tasmania and Northern 
Territory will have their allocation of Metropolitan moved to 
Regional due to the absence of metropolitan areas in these 
locations.
The secondary null hypotheses are that there will 
be no differences between groups A and B or C in 
the proportion of patients who are diagnosed with 
diabetes or pre-diabetes, are referred and take up 
referral to the general practitioner (GP) as well as the 
average costs (direct and indirect) of service delivery 
and incremental longer health benefits from a health 
funder perspective.
The primary clinical hypothesis to be tested is that 
the addition of either an HbA1c POC test (group B) 
or an scBGT POC test (group C) to the AUSDRISK 
assessment will be associated with a statistically signif-
icant increase in the proportions of newly diagnosed 
T2DM cases compared with AUSDRISK alone (group 
A).
Additional clinical hypotheses related to the primary 
hypothesis are that groups B and C will be associated with 
a statistically significant decrease in the proportions of 
those who are referred to the GP, take up referral with 
the GP, are newly diagnosed with pre-diabetes, that is, IFG 
or IGT, and are newly diagnosed with either diabetes or 
pre-diabetes compared with group A.
The economic hypotheses to be tested will take a 
health service funder perspective and involve both trial-
based and modelled components. They are: (1) that the 
addition of either HbA1c POC test or scBGT POC test to 
AUSDRISK screening is cost-effective in comparison with 
AUSDRISK screening alone, having regard to trial-based 
costs and clinical outcomes; (2) that adding either HbA1c 
POC test or scBGT POC test ‘dominates’ AUSDRISK 
screening alone, having regard to modelled longer term 
health and patient outcomes; and (3) that the cost impact 
of adding POC testing to AUSDRISK screening is more 
than offset by the reduction in GP-based costs (fall in false 
positives in trial) and lower treatment costs (modelled 
health outcomes).
MEtHods
trial design
The PDST uses a cluster randomised controlled design 
where pharmacies (clusters) are the unit of randomis-
ation, and screening participants are the unit of anal-
ysis. To ensure the representativeness of the pharmacy 
sample, a geographical method will be used to recruit 363 
pharmacies in all states and territories in Australia to take 
account of population density, residential distribution 
and socioeconomic profile of communities27 (table 1). 
This method will involve data triangulation from several 
sources, including:
 ► a national database of pharmacies with accreditation 
from the Quality Care Pharmacy Program28
 ► postcode boundaries29
 ► socioeconomic indexes for areas (SEIFA) scores and 
deciles from the 2011 (or later on availability) census30
 ► remoteness areas.31
Residential location stratification will be achieved by 
reclassification of the ABS remoteness areas from five to 
three categories as follows: the ABS categories of ‘Inner 
Regional Australia’ and ‘Outer Regional Australia’ will 
be aggregated to a single ‘Regional’ category, and the 
ABS categories of ‘Remote Australia’ and ‘Very Remote 
Australia’ will be aggregated to a single ‘Remote’ cate-
gory. Sampling proportions for ‘Major Cities’ (metropol-
itan) areas of Tasmania and Northern Territory will be 
reallocated to Regional due to the absence of metropol-
itan areas in these jurisdictions.
Geocoded pharmacy locations will be used to extract 
the postcode, the SEIFA scores and remoteness area 
using a spatial join. For each stratum (ie, state or territory 
by remoteness classification shown in table 1), summary 
statistics that provide a description of the socioeconomic 
status conditions across that stratum (eg, major cities of 
New South Wales) will be generated. Each stratum will 
be sorted by postcode in descending order and three 
sequences of postcodes selected. Selecting sequences of 
postcodes typically yields contiguous groups representa-
tive of the stratum from which they are selected. All data 
will be applied at a postcode level.
Pharmacies will be selected from geographical groups 
of colocated postcodes (clusters) and randomly allocated 
to groups A, B or C, each with 121 pharmacies (figure 1). 
The advantage of this is that colocated pharmacies within 
a cluster represent a local community that will all receive 
the same service model to reduce the contamination bias 
between groups.
sample size—screening participants
Sample size calculations will be based on a T2DM inci-
dence of 4.6%32 and allowing for incidence to range 
from 1.4% to 8.5% across the age groups.32 The Cochran-
Mantel-Haenszel (CMH) method33 will be used for the 
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Table 2 Screening participant recruitment quotas by 
gender, age and residential classification (remote, regional 
and metropolitan)
Age groups (years)
Gender
TotalMale Female
35–44 3, 10, 12 3, 10, 12 6, 20, 24
45–54 3, 10, 12 3, 10, 12 6, 20, 24
55–64 3, 10, 12 3, 10, 12 6, 20, 24
65–74 3, 10, 12 3, 10, 12 6, 20, 24
Total 12, 40, 48 12, 40, 48 24, 80, 96
A total sample of 24, 80 and 96 screening participants (stratified by 
age groups and gender) will be recruited from remote, regional and 
metropolitan pharmacies, respectively.
Figure 1 The Pharmacy Diabetes Screening Trial sample. HbA1c, glycated haemoglobin; POC, point of care; scBGT, small 
capillary blood glucose testing.
sample size calculation to account for age groups and 
gender separately. PASS 1434 will be used for sample size 
calculation.
A total sample size of 30 912 screening participants 
(ie, 10 304 per group) is required in order to: (1) detect 
a 30% relative improvement in the ratio of positive 
predictive values (PPVs) of the screening methods (with 
AUSDRISK PPV as baseline), at the 5% significance 
level with 80% power; (2) account for the pharmacy 
clustering effect (ie, the assumed intraclass correla-
tions (ICC) of 0.001 on the proportion scale produced 
a design effect of 1.1 that accounts for correlations 
among screening participants within same cluster); and 
(3) allow for an attrition rate, of those who withdraw or 
who are lost to follow-up, of up to 50%. Given the lack 
of evidence for the true value of ICC, an estimated ICC 
from a cluster randomised controlled trial on screening 
for T2DM and a systematic review summarising ICC 
patterns from primary care research have been used as 
guideline for ICC selection.35 36
To achieve the target sample size of screening partic-
ipants through 363 pharmacies and to account for 
the T2DM incidence range across the age strata,3 the 
recruitment target for each pharmacy will be 96 (metro-
politan), 80 (regional) or 24 (remote) screening partic-
ipants, stratified by gender and age categories (table 2). 
The sample size variation between metropolitan, 
regional and remote pharmacies reflects the fact that a 
‘proportional to residential location sampling strategy’ 
will be adopted.
Pharmacies
To be eligible, a community pharmacy must:
 ► be approved to dispense Pharmaceutical Benefits 
Scheme medicines
 ► have a separate counselling room or private counsel-
ling area
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Figure 2 Clinical protocol. BG, blood glucose; GP, general practitioner; HbA1c, glycated haemoglobin; POC, point of care.
 ► be accredited by an approved Pharmacy Accreditation 
Program
 ► complete a baseline survey of existing screening 
diabetes services being conducted prior to 
commencing participation in the trial
 ► submit a trial implementation plan (via a proforma 
workbook).
All pharmacies in the selected geographical areas will 
be invited to participate and will be included providing 
they meet the eligibility criteria and give informed 
consent. Once they have provided written consent, they 
will be informed of their group allocation.
Pharmacists
Pharmacists who work in a selected pharmacy will be 
eligible to participate if they:
 ► are currently registered by the Australian Health Prac-
titioner Regulation Agency
 ► satisfactorily complete a Continuing Professional 
Development (CPD)-accredited online training 
course and assessment
 ► agree to follow procedures outlined in the trial 
protocol
 ► demonstrate competence in POC testing using the 
device supplied for the trial (groups B and C).
The content for the CPD-accredited online training 
course will be developed by the project team and 
further developed for online delivery by the Guild Phar-
macy Academy. This online training will consist of four 
modules: (1) trial overview; (2) about T2DM; (3) about 
screening; and (4) clinical protocol. Modules 1–3 will be 
the same for all groups, while module 4 is specific to each 
group and supported by standard operating procedures 
detailing each step of the clinical protocol (figure 2). 
The assessment component of the online training 
consists of 16 multiple-choice questions and requires an 
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80% pass mark for accreditation. Pharmacists will receive 
eight CPD points on accreditation and be eligible to 
claim additional CPD points for time spent conducting 
activities relating to the trial. The evaluation compo-
nent of the online learning will include questions about 
their experience and overall level of satisfaction with the 
online training, the relevance of the activity to their prac-
tice and whether the course achieved the stated learning 
objectives.
To ensure consistency in waist measurements within 
and between pharmacies, a Seca 201 waist circumference 
tape measure will be provided to each pharmacy with 
instructions on best practice to take waist circumference 
measurements.37
Pharmacists in groups B and C will receive the Alere 
HbA1c Afinion Analyser AS100 or the Roche Accu-Chek 
Guide Blood Glucose System, respectively, for the duration 
of the trial. All participating pharmacies will receive 
in-pharmacy training sessions delivered by technical 
support representatives who will verify the pharmacist’s 
proficiency in performing a POC test using a competency 
checklist, which is project specific and covers all aspects 
of obtaining a blood sample and use of the equipment. 
In addition, the trainer will make a video recording of 
the performance of the POC test to send to the project 
team for verification of competency. Pharmacists who 
successfully complete the Alere Afinion Analyser AS100 
Analyser or Roche Accu-Chek Guide Blood Glucose System 
training programme may provide training to additional 
participating pharmacists in the trial if required. This also 
requires use of the competency checklist and provision 
of a video to the project team for review and approval of 
new trainees.
screening participants
To be eligible screening participants must:
 ► be aged between 35 and 74 years
 ► not have been previously diagnosed with diabetes or 
pre-diabetes
 ► not have been screened for diabetes in the last 12 
months
 ► not be enrolled in any lifestyle change programmes 
for T2DM
 ► not have a terminal illness or certain blood disorders 
(the latter includes severe haematological diseases, eg, 
thrombocytopaenia and leukaemia; shorter erythro-
cyte lifespan, eg, renal anaemia, chronic and haemo-
lytic anaemia, acute blood loss and recent transfusion; 
haemoglobinopathy and red cell turnover disorders; 
and iron deficiency anaemia)
 ► be able to make independent decisions about their 
health.
Information about specific conditions will be provided 
as part of pharmacist training modules and protocols. 
Eligibility will be assessed on self-report by the prospec-
tive screening participant and based on the pharmacist 
being confident that they can make independent deci-
sions about their health.
clinical protocol
The clinical protocol for the PDST is summarised in 
figure 2 and illustrates the sequential steps of recruit-
ment, AUSDRISK, POC test and referral to the GP.
Promotional material, including flyers and posters, 
will be provided to display in each participating phar-
macy. The recruitment process involves discussing the 
PDST with customers and confirming eligibility in those 
who express an interest in being screened. All pharmacy 
staff, including pharmacists, pharmacy assistants and 
administrative staff, are actively encouraged to support 
the recruitment of screening participants. The expected 
duration of trial recruitment in the pharmacy is 4 months.
The screening appointment commences with the phar-
macist opening a new record using tailored software 
hosted on GuildCare NG, an online cloud-based phar-
macy recording platform, which will provide integrated 
guidance for recruitment and intervention delivery, auto-
mate key processes around patient referral and follow-up 
and enable the required data recording and collection 
for the trial. Eligible screening participants who are inter-
ested in participating will be given a participant infor-
mation sheet to read and be asked to sign two consent 
forms—one to participate in the trial and one to give 
permission for the release of their Medicare data (data 
identifying government-reimbursed health services).
All screening participants will then be asked to 
complete the AUSDRISK and have their waist circum-
ference measured by the pharmacist. GuildCare NG will 
calculate the AUSDRISK score and prompt the next step. 
Screening participants with an AUSDRISK score of <6 will 
receive information on rescreening in 3 years. Screening 
participants with an AUSDRISK score ≥6 will receive 
risk reduction lifestyle information on diet and exer-
cise.38 39 All screening participants with an AUSDRISK 
score of ≥12, in addition to diabetes risk reduction life-
style information on diet and exercise, will also get a list of 
contacts for state-based diabetes prevention programmes 
where available.
The process for referred participants was adapted from 
RACGP guidelines40 through consultation with the PDST 
expert panel. In group A, screening participants with an 
AUSDRISK score of ≥12 will be referred to the GP. In 
group B, screening participants with an AUSDRISK of 
≥12 will receive an HbA1c POC test in the pharmacy 
using the Alere Afinion Analyser and those with an 
HbA1c >39 mmol/mol (5.7%) will be referred to the GP. 
In group C, screening participants with an AUSDRISK 
≥12 will receive a scBGT POC test in the pharmacy using 
the Accu-Chek Guide and those with either a fasting blood 
glucose of ≥5.5 mmol/L (or a random blood glucose 
of ≥7.0 mmol/L) will be referred to the GP. For those 
who qualify for GP referral based on the clinical protocol 
(figure 2), a referral letter outlining their AUSDRISK 
and POC results will be automatically generated and 
given to the screening participant to take to their GP. 
With the screening participant’s consent, the pharma-
cist will also fax the referral letter to the nominated GP. 
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In the event of a very high HbA1c result (ie, ≥75 mmol/
mol (9%)) or blood glucose result (≥15 mmol/L) during 
the screening appointment, GuildCare NG will trigger a 
notification for the pharmacist to arrange an immediate 
appointment with the screening participant’s nominated 
GP.
All referred screening participants will be contacted by 
the pharmacist 6 weeks after the screening appointment 
to check on the status of their recommended follow-up 
with the GP and to motivate referred patients who have 
not yet made an appointment with their GP. Non-referred 
participants will receive a copy of their screening report 
printed from GuildCare NG outlining their risk factors 
and their AUSDRISK results.
Pdst data collection and reporting
The PDST clinical protocol data collection system will 
be purpose designed to operate on the newly developed 
software platform GuildCare NG, which will be provided 
to participating pharmacies with group specific guides 
to support access and familiarisation. Data reports from 
GuildCare NG will be uploaded to Power BI to enable 
monitoring of individual pharmacy recruitment and 
allow early intervention where pharmacies may require 
assistance with recruitment. Regular data files will also be 
supplied to the project team for data analysis as well as 
follow-up and determination of screening outcomes.
Eligible participating pharmacies will receive per-pa-
tient payments (via a payment file in GuildCare NG) for 
each component of the screening service they complete 
as follows: AUSDRISK $10.00; POC test $10.50; and 
Referral $11.00. In addition, at the end of service provi-
sion, a bonus of $750.00 will be provided to the pharma-
cies as an incentive, payable on the completeness of the 
data collected according to the protocol.
clinical outcomes
The screening participants’ referral outcomes will be 
classified as ‘true positives’ or ‘false positives’, based on 
whether they subsequently obtain a T2DM diagnosis, 
respectively. The PPVs of the assessed T2DM screening and 
testing methods will also be calculated to allow compar-
ison with other screening and testing modalities, which 
can be undertaken within the scope of health economic 
evaluation. However, the calculation of ‘true negatives’, 
‘false negatives’ and ‘negative predictive values’ is outside 
the scope of this project.
The outcomes of the GP referral will be determined 
using a stepwise approach involving triangulation of the 
following data sources: (1) contact with the GP practice 
and/or pathology laboratory; (2) a follow-up survey of 
screening participants who were referred to their GP at 
3 months postscreening; and (3) use of Medicare and 
National Diabetes Support Scheme (NDSS) data to iden-
tify items relating to diagnostic testing for diabetes. A 
diagnosis will be considered positive if confirmed by a GP, 
pathology lab, Medicare or NDSS data.
data analyses
The clinical protocol for the PDST (figure 2) will 
adhere to ‘intention-to-treat’ (ITT) principles and 
follow the  Consolidated Standards of Reporting Trials 
(CONSORT) Statement guidelines in reporting the find-
ings41 to include non-attenders as well as those lost to 
follow-up.
Clinical outcome analyses will be based on all 
screening participants who meet the eligibility criteria 
and provide written consent. The null hypothesis of no 
difference between groups will be tested against alterna-
tive hypothesis that either group B or group C will show 
significant differences in clinical and economic outcome 
measures. Since we are only interested in two prespeci-
fied comparisons in this three-armed trial (ie, group A vs 
group B; group A vs group C) and we have a priori expec-
tation about direction of the alternative hypothesis, no 
adjustment is made for multiple comparison.42 43 While 
the direction of alternative hypotheses are prespecified, 
one-tailed tests are avoided, and all statistical tests are 
two-tailed tests.44
For the primary and all secondary clinical outcomes, 
the CMH test will be used to compare the differences in 
proportions of true T2DM detected between groups. This 
will be done by performing CMH tests for group A versus 
group B and group A versus group C comparisons. CMH 
is an efficient approach to compare clustered binary 
outcomes.45 The CMH test takes account of the cluster 
randomisation by considering each pharmacy as a strata 
and allows for variation between the strata in the under-
lying rates. The common OR and its 95% CI will also be 
reported as well as the results of the Breslow-Day test for 
homogeneity of the ORs across the strata. If there is signif-
icant heterogeneity in the ORs, the screening groups will 
also be compared using χ2 tests using separate subset anal-
yses. In further supportive analyses, generalised linear 
mixed models (GLMMs) with binary outcome and logit 
link will be used to simultaneously compare the propor-
tion of newly diagnosed T2DM in group A vs group B and 
group A vs group C. Generalised estimating equations 
approach with working correlation structure and robust 
variance estimator will be used for this purpose.46 GLMMs 
will account for pharmacy clustering effects, baseline 
measurements and explore possible interactions between 
baseline factors and screening methods.
The baseline independent variables of interest are 
gender, age groups and waist circumference of screening 
participants as well as socioeconomic, location and 
remoteness indices of pharmacies (ie, metro, regional 
and remote). Any baseline measure with estimated risk 
greater than 20% according to bivariate or estimation 
using GLMMs will be adjusted for in the multivariate 
models. In additional analyses, random effect logistic 
regression will be used to estimate ICC on logistic scale.
Subgroup analyses will involve testing for associations 
with the primary outcomes for the following additional 
independent variables: baseline pharmacy characteristics, 
socioeconomic profile of the community in which the 
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Figure 3 The Pharmacy Diabetes Screening Trial (PDST) logic model. BGL, blood glucose level; CPA, Community Pharmacy 
Agreement; cRCT, clustered randomised controlled trial; GP, general practitioner; HbA1c, glycated haemoglobin; ICERs, 
incremental cost-effectiveness ratios; PHN, Primary Health Network; POC, point of care; T2DM, type 2 diabetes mellitus.
pharmacy is located, different threshold of AUSDRISK, 
and different thresholds for blood tests, nature and 
extent of counselling after screening, and successful 
completion of the 6-week follow-up. Other intended 
substudies include analyses to determine factors associ-
ated with uptake of referral to GP and subsequent diag-
nostic testing, as well as factors associated with pharmacy 
performance during the trial (recruitment rates and 
intervention fidelity).
Missing values will be scrutinised to check for 
non-random distribution and analyses that use baseline 
data will be executed twice: once using observed data, 
and once using the multiple imputation (MI) method.47 
Participant characteristics and other important measures, 
such as AUSDRISK results, will be compared in complete 
and missing data in order to detect systematic patterns 
in missing data. Sensitivity analysis will be conducted to 
evaluate random assumptions for missing follow-up data, 
which will be imputed assuming missing not at random 
(MNAR) in all three arms. Robustness of the findings 
under different MNAR assumptions will be examined by 
imputing missing data using the MI approach. The sensi-
tivity analyses will account for all randomised participants. 
The first set of MIs assume missing at random, while the 
other sets of MIs will be implemented under MNAR 
assumptions. In MNAR scenarios imputation of missing 
outcomes will be associated with higher risk (ie, higher 
diabetes proportion) in group B and group C compared 
with group A. All reasonable scenarios will be considered 
in the sensitivity analyses. The robustness of the conclusion 
with regard to the treatment difference will be evaluated 
across these scenarios, and a range of profiles for undiag-
nosed diabetes due to missing follow-up referral will be 
examined for their impact on the study conclusion.48
Pdst evaluation
A logic model (figure 3) summarises the steps in the 
PDST programme development, implementation and 
projected outcomes. This logic will be used to frame our 
approach to evaluating: (1) whether the PDST was imple-
mented as intended (fidelity and reach); (2) the way in 
which study outcomes were achieved or not achieved; 
and (3) the influence of situational factors on the results 
obtained. Baseline survey data, screening data and phar-
macist interview transcripts will be used to assess these 
issues.
baseline evaluation
At the beginning of the trial, participating pharmacies will 
be required to complete a baseline survey that includes 
questions on pharmacy characteristics, existing profes-
sional services and strategies used for implementing 
these services. This information will be used to inform the 
comparability of trial arms and health economic analysis.
screening data
All data entered into GuildCare NG during screening 
by pharmacists will be extracted centrally to enable 
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quantitative elements of process evaluation around the 
screening process.
Midtrial interviews
Two months after completion of online training, a mix of 
pharmacists from high-performing and low-performing 
pharmacies in all three trial arms will be invited to 
provide feedback individually or as part of a focus group 
involving participants from their trial arm. The purpose 
of obtaining feedback will be to identify challenges, 
opportunities, barriers and facilitators to service imple-
mentation. This will be used by researchers to conduct a 
midtrial review of pharmacy support and processes, with 
adaptation where feasible and dissemination of effective 
implementation strategies identified.
End-of-trial interviews
At the end of the trial, a number of surveys, telephone 
questionnaires/interviews and focus groups will be 
conducted as follows:
1. A purposive sample of 10% of participating phar-
macists, representing a mix of high recruitment and 
low recruitment, will be invited to participate in sem-
istructured interviews and focus groups to gain feed-
back on service implementation in the pharmacy, 
including barriers and facilitators to implementing 
the trial in the pharmacy, perceptions of sustainability 
and level of engagement by locals GP in the referral 
process.
2.  All referred participants will receive an online survey 
to determine the outcome of the referral, as well as 
their level of satisfaction with the service.
3.  A random sample of 20% of non-referred screening 
participants will be surveyed to determine their over-
all experience and level of satisfaction with the ser-
vice.
4.  A random sample of 10% of GPs who had patients 
referred to them during the trial will be invited to 
respond to a telephone questionnaire to determine 
their overall experience and level of satisfaction with 
the service.
All surveys will be created using recognised survey soft-
ware, for example, Research Electronic Data Capture 
(REDCap)49, a secure web-based application designed to 
support data capture for research studies hosted at the 
University of Sydney. REDCap provides an intuitive inter-
face for validated data entry, audit trails for tracking data 
manipulation and export procedures, automated export 
procedures for seamless data downloads to common 
statistical packages and procedures for importing data 
from external sources.
Qualitative interviews will be conducted with the aid 
of the ethics approved semistructured interview guide, 
which will comprise open-ended questions that prompt 
discussion on a wide range of topics including their 
experience with the PDST, consumer feedback, interac-
tion with GPs and impact of the trial in their pharmacy. 
Qualitative interviews will be conducted by members of 
the research team, and a maximum variation sample of 
PDST pharmacists, reflecting a range of location, capacity 
and indicators of trial success, will be invited to partici-
pate in either individual interviews or focus groups. The 
interview process will continue until data saturation is 
achieved. Interviews will be audiotaped and transcribed 
verbatim, and a thematic analysis performed using stan-
dard qualitative approaches. NVivo software will be used 
as a tool in identifying, labelling and organising themes.
Impact evaluation
This will be determined by testing the clinical hypotheses 
of the trial as previously outlined in sections ‘Clinical 
Protocol’ and ‘Clinical Outcomes’.
Economic evaluation
A ‘cost-effectiveness analysis’ will be conducted from 
a health service funder perspective that includes costs 
borne by the pharmacists, the government (Medicare 
Benefits Scheme (MBS) items) and the PDST administra-
tion. Costs borne by the patients (eg, copayments charged 
by GPs) are not included in the analysis.
The core hypothesis for the economic analysis is that 
addition of either the HbA1c POC test or the scBGT 
POC test to AUSDRISK screening followed by a referral 
to GP, if appropriate, is cost-effective in comparison with 
AUSDRISK screening alone. The ‘net cost per confirmed 
new T2DM diagnosis’ for each group will be estimated 
and compared. We will assess whether the average cost 
of the new T2DM case in either of the POC intervention 
groups is lower or higher than the average cost of the new 
T2DM case in the AUSDRISK alone group.
There is likely to be a difference in average costs per 
new T2DM diagnosis across the sites in the same cluster 
and across the clusters from the metropolitan, regional 
and remote settings. This is due to the difference in the 
numbers of the recruited patients (that can defy the 
predetermined sample size), local unit prices, staff mix 
and established local practices. The source of variation 
(if observed) as well as the cost drivers will be investigated 
with a generalised linear model using one of the standard 
statistical software packages (SPSS V.24 or STATA V.14).
In addition to preparation of average cost-effectiveness 
ratios per group, incremental cost-effectiveness ratios 
(ICERs) will also be prepared that allow fuller analysis 
of incremental costs across various comparator combina-
tions in various settings.
Depending on the trial-based outcomes, the cost-ef-
fectiveness analysis conducted alongside the trial (time 
horizon determined according to average time from 
screening to the confirmation of T2DM status based on 
the lab test results), will be complemented by a modelled 
economic evaluation with an extended time horizon (eg, 
the expected lifetime for each age subgroup of the eligible 
population). The modelled economic evaluation would 
translate the benefits of early diagnosis of T2DM and 
the associated prevention/delay of the T2DM complica-
tions into final health benefits, assessed in life-years saved 
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and quality-adjusted life-years (QALYs). The modelled 
economic evaluation will depict the processes and clin-
ical management algorithms beyond the point of T2DM 
diagnosis (ie, ‘within trial’ observation period) and will 
include the costs of treatment, regular laboratory inves-
tigations, treatment of adverse events, hospital admis-
sions and other relevant costs. The long-term improved 
outcomes are hypothesised to translate in a cost reduc-
tion and offset the increased costs associated with adding 
pharmacy-based screening for T2DM to the GP-based 
diagnosis services. The modelled economic evaluation 
will draw on the published results of long-term observa-
tional studies in order to derive assumptions for the deci-
sion analytic modelling and to populate the model. An 
appropriate discount rate will be applied to both costs 
and benefits incurred over the longer time horizon.
In the cost analysis, both fixed and variable costs will be 
assessed. The former will include durable items of equip-
ment, time involved in the development of materials 
(including the online materials) used in the preparation 
for and administration of the service, staff training and 
IT input into developing a software platform for collec-
tion of patient personal and medical data. The variable 
costs also include the promotional resources kit, POC kit, 
disposable materials, blanks of the questionnaires and so 
on. The sources for the cost data include the screening 
participants’ records entered by the pharmacies into 
GuildCare NG, MBS data and pharmacists’ reports on 
the time spent on screening/testing the screening partic-
ipants. The reports can be complemented by the direct 
observations at randomly selected pharmacies.
The variability in effect sizes and cost differences gener-
ates a degree of uncertainty, while any uncertainty in 
these parameters translates into uncertainty in the ICER 
estimate. However, generating a 95% CI for an ICER is 
problematic as the ratio of the two distributions does not 
necessarily have a finite mean or, therefore, a finite vari-
ance.50 The uncertainty about results of economic evalu-
ation, that is, around the ICER estimate, will be explored 
using a non-parametric bootstrapping method with at 
least 1000 resampling draws. Results will be plotted on 
the cost-effectiveness plane to illustrate the uncertainty 
cloud and also on an acceptability curve to illustrate the 
certainty of a cost-effective result for a chosen threshold 
(eg, 90% confidence levels of all ICER results are <$50 
000 per QALY). The CI is estimated by using percentile 
interval method as a quasi-CI, since the non-parametric 
bootstrap method does not produce a true statistical 
inference for a proportion. Although the accuracy of 
estimation using the percentile interval could be poten-
tially compromised, the method is commonly used in 
economic evaluation. This reflects its ease of use, accept-
able rigour and advantages in communicating research 
findings to a broader audience, including policy makers 
and clinicians.
Interpretation of the results would depend on the 
position of the distribution of bootstrapped ICERs on 
the cost-effectiveness plane. If the AUSDRISK alone 
assessment is associated with a higher rate of false posi-
tive cases, then it may attract higher costs.50 For example, 
for an intervention that is more effective and more costly 
than the comparator, the positive decision to invest would 
depend on the decision maker’s maximum willingness 
to pay per additional unit of the outcome, that is, per 
additional case of new T2DM diagnosis. Alternatively, if 
‘dominance’ is demonstrated (ie, POC intervention arms 
cheaper than AUSRISK screening alone for the same or 
better health outcomes), then efficiency is clearly evident.
Brief mention was made above of financial appraisal 
being specified alongside economic appraisal. This is 
important to clarify in the protocol as it impacts on how 
the economic analysis is conducted. It is not uncommon, 
for example, that where costs occur in all arms of a trial, 
for these costs to be excluded from the economic analysis 
as not influencing the ICERs. This may become problem-
atic later on, however, if decision makers want to know 
the full budget required to implement the initiative eval-
uated. Financial appraisal and full pathway costing will 
be undertaken as part of this trial. Where assumptions 
for the identification, measurement and valuation of 
economic costs differ to financial costs, these differences 
will be specified.
The results of process, impact and economic evaluation 
will determine the most clinically effective and cost-effec-
tive screening model as well as the feasibility of its future 
translation and sustainability in community pharmacy.
Ethics and dissemination
The protocol has been approved by the Human Research 
Ethics Committees at University of Sydney and Deakin 
University. Results will be available on the Sixth Commu-
nity Pharmacy Agreement (6CPA) website and will be 
published in peer-reviewed journals.
Approval has been granted from the Australian 
Government Department of Human Resources to obtain 
screening participants’ MBS items relating to claimed 
fees for health service provision during the trial.
dIscussIon
A comparative analysis will establish whether an elevated 
AUSDRISK risk score combined with an elevated POC 
test result (groups B and C) is more clinically effective 
and cost-effective than the AUSDRISK elevated risk score 
alone at detecting T2DM in the community.
It has previously been shown that pharmacy-based 
screening for T2DM, using a combination of a risk assess-
ment tool followed by a scBGT POC test, was associated 
with a statistically significant increase in the proportion of 
newly diagnosed T2DM cases, although the proportion of 
false positive results (based on an ITT analysis) was high 
in both the intervention and the comparator arms.24 The 
PDST aims to expand this study to a much larger scale, 
as well as refining the protocol by using the AUSDRISK 
diabetes risk assessment tool, which is currently the 
benchmark for use in general practice throughout 
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Australia, as well as including a group that uses HbA1c 
POC test for those with AUSDRISK ≥12, compared 
with scBGT POC test for those with AUSDRISK ≥12 or 
AUSDRISK ≥12 alone.
The protocol for this pharmacy-based screening trial is 
centred on correctly identifying diabetes risk factors and 
referring those who meet the criteria to a GP for further 
testing and possible diagnosis. The thresholds for HbA1c, 
fasting and random blood glucose used for identifying 
people at risk in this trial are set lower than those used 
for diagnostic tests.40 This is to minimise false negatives, 
that is, those with the disease who do not meet the criteria 
for referral to the GP, which by default will result in more 
false positives, that is, those without the disease that meet 
the criteria for referral to the GP. These parameters have 
important health status and cost implications, which are 
useful for policy analysis. A high false positive rate, for 
example, adds substantial follow-up/confirmation costs 
to the screening pathway, as well as unnecessary patient 
anxiety. A high false negative rate, however, would mean 
patients with diabetes are being missed by the screening 
algorithm that may have serious adverse consequences.
The overall expected attrition rate of 50% may include 
disproportionate withdrawal from particular groups. To 
reduce the impact of any potential bias, the ITT analysis 
will include all screening participants in the final anal-
ysis, regardless of non-compliance or withdrawal. ITT is 
also appropriate and preferred from an economic eval-
uation perspective for allocative efficiency but would not 
exclude ‘per protocol’ analysis to examine technical effi-
ciency issues related to intervention design and degree of 
exposure. Medicare data will be used, where possible, to 
estimate the outcomes for those lost to follow-up.
Pharmacies that represent a wide range of local demo-
graphics and regions across Australia will be selected to 
participate in the PDST. The representative and random 
nature of pharmacy recruitment will also inform the 
potential real-world effectiveness of each intervention at 
a population level. However, while every effort has been 
made to provide standardised approaches and clear docu-
mentation, as well as appropriate answer fields to mini-
mise errors in participant responses, we acknowledge that 
some data obtained from pharmacists may be inaccurate 
or incomplete. In addition, recruitment of screening 
participants may not have the expected uptake, and we 
may be unable to verify whether a diagnosis of T2DM or 
pre-diabetes was made for a small proportion of referred 
screening participants whose diabetes testing does not 
trigger NDSS registration, and where follow-up with the 
patient, pathology lab and GP cannot be achieved or 
otherwise fails to confirm an outcome.
As the prevalence of T2DM continues to rise, there 
is a need for novel programmes that provide effective 
screening for undiagnosed T2DM that can reach into 
all areas of Australia. The PDST addresses goal 2 of 
the Australian National Diabetes Strategy,19 that is, to 
promote awareness and early detection in that it enables 
opportunistic screening of individuals during routine 
encounters with the community pharmacy in a previously 
undiagnosed population. The clinical analyses will eval-
uate which service has the most reliability and validity, 
while minimising discomfort and harm. The economic 
analyses will detail the costs of providing each service 
protocol and measure against cost impacts to the health-
care system. The process evaluation will provide infor-
mation on how the trial service fits into the day-to-day 
operations of the pharmacy and its sustainability as well 
as satisfaction with the service from participants and GPs. 
A screening programme that is clinically effective, cost-ef-
fective and sustainable will result in many benefits and 
reduce the burden on the individual, the community and 
the health system.
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